2269:HKEXWuxi Biologics (Cayman) Inc. Analysis

WuXi Biologics (2269.HK) is trading at HK$31.08, marginally above its DCF fair value of HK$30.65 but still offering roughly 50% upside to analyst median target of HK$46.84. The company posted HK$21.79 bn in revenue with a robust 17.2% YoY growth, solid gross margin of 46%, operating margin of 33% and a profit margin of 22.5%. Forward EPS is projected at HK$1.99, implying a forward P/E of 15.6**, well below the industry average P/E of 24.8. Technicals are bearish – price sits below the 20‑, 50‑ and 200‑day SMAs, MACD is in a bearish configuration and RSI is neutral at 43, while volatility remains high at 48%** over the past 30 days. Recent material news highlights the GMP release of the new DP15 drug‑product facility in Shanghai and inclusion in the Dow Jones Best‑in‑Class World Index, underscoring operational expansion and market recognition.